Nyxoah Announces Financial and Operational Outcomes for Q2

August 19, 2025 - 01:08

Mont-Saint-Guibert, Belgium – August 18, 2025 – Nyxoah SA, a pioneering medical technology firm specializing in innovative treatments for Obstructive Sleep Apnea (OSA) through neuromodulation, has disclosed its financial and operational results for the second quarter of the fiscal year.

In a significant development, the U.S. Food and Drug Administration (FDA) has granted approval for the Genio® System, marking a pivotal moment for the company as it embarks on its commercial launch within the U.S. market. This approval is expected to enhance Nyxoah's market presence and provide patients with a new, effective treatment option for OSA.

The company has reported a notable increase in revenue compared to the previous quarter, driven by heightened demand for its innovative solutions. Nyxoah remains committed to advancing its product offerings and expanding its reach in the healthcare sector, aiming to improve the quality of life for individuals suffering from sleep-related disorders.

As Nyxoah moves forward, the focus will be on leveraging the recent FDA approval to maximize the potential of the Genio® System and strengthen its position in the competitive landscape of medical technology.